NDA 205352 · Bayer Hlthcare
Aleve Pm
Diphenhydramine Hydrochloride, Naproxen Sodium · Oral
Last checked: Nov 19, 2026Latest source record: Feb 8, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jan 17, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,141
246 Phase 3, 67 recruiting
FAERS reports
2,033
189 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 4, 2025.
Uses for relief of occasional sleeplessness when associated with minor aches and pains helps you fall asleep and stay asleep
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 17, 2014 Original approval · Type 4 - New Combination Summary ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- ALEVE PM · DIPHENHYDRAMINE HYDROCHLORIDE 25MG; NAPROXEN SODIUM 220MG · TABLET, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Diphenhydramine" as an intervention, any sponsor and status, largest first.
Boehringer IngelheimBoehringer Ingelheim
NCT00153101 · 31,546 participants · Start Nov 2001 · Primary completion Jun 2008
Drug: Telmisartan; Combination of Telmisartan and Ramipril and 1 more · For: Cardiovascular Diseases
Sites: Athens, Alabama; Birmingham, Alabama; Phoenix, Arizona · 732 sites in all
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- PRoFESS - Prevention Regimen For Effectively Avoiding Second StrokesPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00153062 · 20,332 participants · Start Aug 2003 · Primary completion Apr 2008
Drug: Aggrenox; Aggrenox and 10 more · For: Stroke
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 667 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT01011660 · 13,542 participants (planned) · Start Oct 2007 · Primary completion Aug 2012
Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin · For: Essential Hypertension
Sites: Beijing, China
- Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00249795 · 9,016 participants · Start Jun 2003 · Primary completion Aug 2009
Drug: Irbesartan; placebo · For: Atrial Fibrillation; Cardiovascular Disease
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 30 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use issue466
- drug ineffective461
- insomnia185
- medication error133
- product use in unapproved indication113
- somnolence113
- therapeutic response unexpected103
- incorrect drug administration duration101
- incorrect dose administered73
- expired product administered61
- drug ineffective for unapproved indication60
- feeling abnormal59
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2014 | 184 |
| 2015 | 521 |
| 2016 | 358 |
| 2017 | 225 |
| 2018 | 236 |
| 2019 | 246 |
| 2020 | 87 |
| 2021 | 54 |
| 2022 | 40 |
| 2023 | 21 |
| 2024 | 30 |
| 2025 | 15 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of acute urticaria: A systematic review.
Badloe FMS, Grosber M, Ring J, et al. · J Eur Acad Dermatol Venereol 2024 · Systematic Review
- Efficacy and safety of hydroxyzine for sleep in adults: Systematic review.
Burgazli CR, Rana KB, Brown JN, et al. · Hum Psychopharmacol 2023 · Systematic Review
- Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Fornaro M, Caiazza C, Solini N, et al. · Mol Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Supportive care and antiviral treatments in primary herpetic gingivostomatitis: a systematic review.
Coppola N, Cantile T, Adamo D, et al. · Clin Oral Investig 2023 · Systematic Review
- Standardized Extract of Valeriana officinalis Improves Overall Sleep Quality in Human Subjects with Sleep Complaints: A Randomized, Double-Blind, Placebo-Controlled, Clinical Study.
Chandra Shekhar H, Joshua L, Thomas JV · Adv Ther 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Honey for acute cough in children.
Oduwole O, Udoh EE, Oyo-Ita A, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Systematic Review
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.